

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 July 2025 (10.07.2025)



(10) International Publication Number
WO 2025/146458 A1

(51) International Patent Classification:

<i>A61K 38/18</i> (2006.01)	<i>A61P 9/10</i> (2006.01)
<i>A61P 1/16</i> (2006.01)	<i>A61P 11/00</i> (2006.01)
<i>A61P 3/04</i> (2006.01)	<i>A61P 13/12</i> (2006.01)
<i>A61P 3/08</i> (2006.01)	<i>A61P 15/00</i> (2006.01)
<i>A61P 3/10</i> (2006.01)	<i>A61P 19/02</i> (2006.01)
<i>A61P 9/00</i> (2006.01)	<i>A61P 29/00</i> (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2025/050048

(22) International Filing Date:

02 January 2025 (02.01.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2400055.6 03 January 2024 (03.01.2024) GB

(71) Applicant: **TRIBUNE THERAPEUTICS AB** [SE/SE];
C/O Healthcap VIII Advisor AB, Engelbrektsplan 1, 114 34
Stockholm (SE).

(72) Inventor: **KAASBØLL, Ole Jørgen**; Tribune Therapeu-
tics AB, C/O Healthcap VIII Advisor AB, Engelbrektsplan
1, 114 34 Stockholm (SE).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: USE OF CCN DOMAIN-CONTAINING PROTEINS FOR THE TREATMENT OF DISEASE

(57) Abstract: The present invention relates to the treatment of disease, and particularly to the use of active agents containing CCN
dIII domain sequences for the treatment of obesity and polycystic kidney disease.

WO 2025/146458 A1